The role of the epidermal growth factor receptor in breast cancer

被引：58

作者：

Chan, Samuel K.

Hill, Mark E.

Gullick, William J. ^{[1
]}

机构：

[1] Univ Kent, Canc Biol Lab, Res Sch Biosci, Canterbury CT2 7NJ, Kent, England

[2] Kent Oncol Ctr, Maidstone, Kent, England

来源：

JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA | 2006年 / 11卷 / 01期

关键词：

breast; ErbB; EGFR; signal transduction; hormone resistance; gefitinib; erlotinib;

D O I：

10.1007/s10911-006-9008-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recent trials of drug therapy targeting the erbB receptor HER2 have met with success in breast cancer. The epidermal growth factor receptor or EGFR is a closely related receptor from this same family that is involved in cellular signal transduction and tumor cell growth and survival. Emerging evidence indicates that EGFR is implicated in the development of hormone-resistant breast cancer, and that its activity is intertwined with estrogen receptor. Here, the role of EGFR in breast cancer is reviewed, and data from selected clinical trials of signal transduction inhibition of this cellular target are summarized.

引用

页码：3 / 11

页数：9

共 78 条

[51] A Multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer [J].

Miller, KD ;

Trigo, JM ;

Wheeler, C ;

Barge, A ;

Rowbottom, J ;

Sledge, G ;

Baselga, J .

CLINICAL CANCER RESEARCH, 2005, 11 (09) :3369-3376

[52]

MITA M, 2005, SAN ANT BREAST CANC

[53] Nonendocrine pathways and endocrine resistance: Observations with antiestrogens and signal transduction inhibitors in combination [J].

Nicholson, RI ;

Hutcheson, IR ;

Knowlden, JM ;

Jones, HE ;

Harper, ME ;

Jordan, N ;

Hiscox, SE ;

Barrow, D ;

Gee, JMW .

CLINICAL CANCER RESEARCH, 2004, 10 (01) :346S-354S

[54] Endocrine therapy - current benefits and limitations [J].

Nicholson, RI ;

Johnston, SR .

BREAST CANCER RESEARCH AND TREATMENT, 2005, 93 (Suppl 1) :S3-S10

[55] Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer [J].

Nicholson, RI ;

Hutcheson, IR ;

Harper, ME ;

Knowlden, JM ;

Barrow, D ;

McClelland, RA ;

Jones, HE ;

Wakeling, AE ;

Gee, JMW .

HORMONE-RELATED TUMORS: NOVEL APPROACHES TO PREVENTION AND TREATMENT, 2002, 963 :104-115

[56] EGFR and cancer prognosis [J].

Nicholson, RI ;

Gee, JMW ;

Harper, ME .

EUROPEAN JOURNAL OF CANCER, 2001, 37 :S9-S15

[57] Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth [J].

Normanno, N ;

Campiglio, M ;

De Luca, A ;

Somenzi, G ;

Maiello, M ;

Ciardiello, F ;

Gianni, L ;

Salomon, DS ;

Menard, S .

ANNALS OF ONCOLOGY, 2002, 13 (01) :65-72

[58] Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells [J].

Okubo, S ;

Kurebayashi, J ;

Otsuki, T ;

Yamamoto, Y ;

Tanaka, K ;

Sonoo, H .

BRITISH JOURNAL OF CANCER, 2004, 90 (01) :236-244

[59] Molecular portraits of human breast tumours [J].

Perou, CM ;

Sorlie, T ;

Eisen, MB ;

van de Rijn, M ;

Jeffrey, SS ;

Rees, CA ;

Pollack, JR ;

Ross, DT ;

Johnsen, H ;

Akslen, LA ;

Fluge, O ;

Pergamenschikov, A ;

Williams, C ;

Zhu, SX ;

Lonning, PE ;

Borresen-Dale, AL ;

Brown, PO ;

Botstein, D .

NATURE, 2000, 406 (6797) :747-752

[60] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer [J].

Piccart-Gebhart, MJ ;

Procter, M ;

Leyland-Jones, B ;

Goldhirsch, A ;

Untch, M ;

Smith, I ;

Gianni, L ;

Baselga, J ;

Bell, R ;

Jackisch, C ;

Cameron, D ;

Dowsett, M ;

Barrios, CH ;

Steger, G ;

Huang, CS ;

Andersson, M ;

Inbar, M ;

Lichinitser, M ;

Láng, I ;

Nitz, U ;

Iwata, H ;

Thomssen, C ;

Lohrisch, C ;

Suter, TM ;

Ruschoff, J ;

Süto, T ;

Greatorex, V ;

Ward, C ;

Straehle, C ;

McFadden, E ;

Dolci, MS ;

Gelber, RD .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1659-1672

← 1 2 3 4 5 6 7 8 →